cemiplimab
regeneron,sanofi
['empower-cervical 1', 'cemiplimab', 'agent', 'gyn']
findings from long-term follow-up of the empower-cervical 1 study demonstrated that cemiplimab improved survival vs chemotherapy and resulted in a safety profile like other anti pd-l1 agents. #gyncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.